PharmaTher Holdings Ltd (TSE:PHRM) has released an update.
PharmaTher’s affiliate Sairiyo Therapeutics has applied to initiate a Phase 1 clinical trial in Australia for a reformulated version of cepharanthine, aimed at treating infectious diseases and cancer. The study will evaluate the bioavailability and pharmacokinetics of the drug, with the potential to receive a substantial tax rebate under Australia’s R&D incentive program. Following the trial, Sairiyo plans to seek FDA approval to proceed with further clinical trials in the U.S.
For further insights into TSE:PHRM stock, check out TipRanks’ Stock Analysis page.
